OrthoPediatrics Corp. Files Sanctions Motion Against a Former Employee and WishBone Medical, Inc.

WARSAW, Indiana, Jan. 02, 2019 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today issued a statement from Daniel Gerritzen, Vice President and General Counsel, concerning actions it filed against Robert von Seggern, a former employee, and WishBone Medical, Inc. in an Indiana state court in late December 2018 (the “Sanctions Motion”).  These actions are part of OrthoPediatrics’ existing lawsuit against von Seggern and WishBone Medical for, in part, violations of Indiana’s and federal trade secrets statutes (OrthoPediatrics Corp. v. Robert von Seggern & WishBone Medical, Inc. Whitley Superior Court, Cause No. 92D01-1705-PL-000150).

The underlying lawsuit alleges that von Seggern stole OrthoPediatrics’ trade secrets and confidential information and then turned those over to WishBone Medical for its use in developing pediatric orthopedic products.  The Sanctions Motion requests the Whitley Superior Court to sanction von Seggern and WishBone Medical for their repeated, deliberate efforts to subvert the discovery process by refusing to produce responsive documents and information, hiding or otherwise destroying evidence, and making misstatements to OrthoPediatrics and the Court concerning the existence of responsive documents and its efforts to find and produce such materials.

“OrthoPediatrics welcomes legitimate competition because that means more kids with pediatric orthopedic conditions will have greater opportunities to be helped,” stated Gerritzen.  “However, we will not tolerate individuals or entities misappropriating our property, in part, to leapfrog years of design and testing work and avoid the significant monetary expense of bringing competing products to market.  With this in mind, we will continue to aggressively pursue every legal remedy to protect and safeguard our research and product development efforts to improve the lives of children with pediatric conditions.  This includes holding those accountable who attempt to use, without authorization, OrthoPediatrics’ trade secrets and confidential information.  The trade secrets and confidential information we have become aware von Seggern and WishBone Medical misappropriated relates to aspects of our current Trauma and Deformity Correction medical devices.  While very serious, the misappropriation does not significantly jeopardize our overall research and development pipeline.”

Gerritzen continued, “OrthoPediatrics takes active measures to protect its trade secrets and confidential information.  These safeguards continue to be refined and adapted in light of ever-changing threats. Due to its ongoing lawsuit, OrthoPediatrics will not provide any additional comments or details regarding this matter other than what is reflected in court filings and Court orders.”

Artificial Intelligence in Healthcare Spending to Hit $36B

By Jennifer Bresnick

 – The global market for artificial intelligence in healthcare is set for incredible growth over the next few years, according to new research from ReportLinker.

The AI in healthcare market is slated to expand from its current $2.1 billion to $36.1 billion in 2025, representing a staggering compound annual growth rate (CAGR) of 50.2 percent.

This rapid increase in value for a relatively new but highly impactful market will be driven largely by North American investment, with the United States at the forefront of innovation and spending.

Hospitals and physician providers will be the major investors in machine learning and artificial intelligence solutions and services, the report predicts.

“A few major factors responsible for the high share of the hospitals and providers segment include a large number of applications of AI solutions across provider settings; ability of AI systems to improve care delivery, patient experience, and bring down costs; and growing adoption of electronic health records by healthcare organizations,” said the report.

“Moreover, AI-based tools, such as voice recognition software and clinical decision support systems, help streamline workflow processes in hospitals, lower cost, improve care delivery, and enhance patient experience.”

Natural language processing (NLP) tools will play an important role in bringing these improvements to providers, continued the brief.

NLP can translate speech into text, extract concrete data elements from unstructured input, and power chatbots that offer customer service or even basic triage for low-level complaints.

These services will be valuable to consumers seeking more convenient, on-demand access to care as well as among providers looking to reduce their keyboard time and simplify interactions with their electronic health records (EHRs).

Using artificial intelligence to create more intuitive, user-friendly workflows is a top goal for EHR developers moving into 2019, especially as provider burnout continues to rise and dissatisfaction with existing products hits a fever pitch.

Traditionally consumer-focused companies, such as Google and Amazon, are also rising to the challenge of creating AI-driven tools that can leverage NLP to capture key medical interactions and improve home monitoring for individuals with chronic disease.

Combining machine learning with medical-grade or consumer-facing devices may exponentially increase the impact of both technologies, notes a separate report from Frost & Sullivan published in September of 2018.

Developing Internet of Medical Things (IoMT) strategies that match sophisticated sensors with AI-backed analytics will be key for developing the smart hospitals – and smart homes – of the future.

“Sensors, artificial intelligence, big data analytics, and blockchain are vital technologies for IoMT as they provide multiple benefits to patients and facilities alike,” said Varun Babu, Senior Research Analyst, TechVision.

“For instance, they help with the delivery of targeted and personalized medicine while simultaneously ensuring seamless communication and high productivity within smart hospitals.”

These strategies are likely to contribute significantly to the predicted growth of the general artificial intelligence market as devices become smaller, cheaper, and more accepted by consumers and providers alike.




DOJ recovered $2.5 billion in 2018 healthcare false claim cases

Dec 26, 2018 / By KEVIN TRUONG

As part of the federal government’s increasing focus on issues of healthcare fraud, particularly in the Medicare space, the U.S. Department of Justice recovered $2.5 billion in settlements and judgments from False Claims Act Cases over the past year.

According to the DOJ, this is the ninth consecutive year that the organizations’ civil health care fraud settlements and judgments have exceeded $2 billion.

While the $2.5 billion number represents federal losses, the DOJ also said it also helped recover significant funds for state Medicaid programs

“Every year, the submission of false claims to the government cheats the American taxpayer out of billions of dollars,” Principal Deputy Associate Attorney General Jesse Panuccio said in a statement.

“In some cases, unscrupulous actors undermine federal healthcare programs or circumvent safeguards meant to protect the public health … The nearly three billion dollars recovered by the Civil Division represents the Department’s continued commitment to fighting fraudsters and cheats on behalf of the American taxpayer.”

The False Claims Act has its roots in groups trying to defraud the military during and after the Civil War and was significantly strengthened since 1986 when Congress increased incentives for whistleblowers to file lawsuits alleging false claims.

In healthcare, organizations across the industry were hit with False Claims cases including drug companies, medical device manufacturers, payer organizations and healthcare providers.




The Hidden System That Explains How Your Doctor Makes Referrals

Dec. 27, 2018 / By Anna Wilde Mathews and Melanie Evans

Phoebe Putney Health System doesn’t want its doctors to send business to competitors. If they do, Phoebe makes sure their bosses know about it.

Doctors working for the Albany, Ga.-based hospital system’s affiliated physician group get regular reports breaking down their referrals to specialists or services. One viewed by The Wall Street Journal included cardiology, colonoscopies and speech therapy, along with the share of each referred to Phoebe health-care providers.

If the share of in-house business wasn’t viewed as adequate, administrators would press them to improve, doctors said.

“They would let you know it wasn’t high enough,” said Thomas Hilsman, a primary-care doctor recently retired from the Phoebe medical group. He said he felt referrals should be based on which health-care provider was best for patients. “They keep the Phoebe physicians busy, they see more patients, they make more money.”

Phoebe officials said they use referral policies to improve quality and reduce costs, and physicians weren’t punished for their decisions.

Patients are often in the dark about why their doctors referred them to a particular physician or facility. Increasingly, those calls are being driven by pressure to keep business within a hospital system, even if an outside referral might benefit the patient, according to documents and interviews with doctors, current and former hospital executives and lawyers.

Losing patients to competitors is known as “leakage.” Hospitals, in response, use an array of strategies to encourage “keepage” within their systems, which in recent years have expanded their array of services.

The efforts at “keepage” can mean higher costs for patients and the employers that insure them—health-care services are often more expensive when provided by a hospital. Such price pressure and lack of transparency are helping drive rising costs in the $3.5 trillion U.S. health-care industry, where per capita spending is higher than any other developed nation.

For hospital systems, doctors’ referrals are a vital source of revenue. A hospital earns an average of $1.8 million annually in revenue from an internal-medicine physician’s admissions, referrals for tests and other services, plus practice revenue for employed doctors, a 2016 survey by recruiter Merritt Hawkins, a unit of AMN Healthcare Services Inc., found. The survey didn’t include hospital revenue from referrals by internal-medicine doctors to specialists, such as orthopedic surgeons or cardiologists.

Hospitals have gained more power over doctors with a wave of acquisitions of practices and hirings in recent years, and hospitals are getting more aggressive in directing how physicians refer for things such as surgeries, specialty care and magnetic resonance imaging scans, or MRIs.




Year in review: The provider mergers that made headlines in 2018

by Paige Minemyer | 

Providers have yet to slake their thirst for mergers—with several big-ticket mega-deals dominating headlines in 2018—but experts warn that there’s unlikely to be an immediate pay off for patients.

And despite the fast pace of consolidation in healthcare, there are no signs of the merger trend slowing down going into 2019, especially as private equity investors have their focus squarely on the opportunities in the industry.

Some of the most notable deals of 2018 included the $28 billion merger between Catholic Health Initiatives and Dignity Health, forming one of the largest non-profit systems in the country, and the ongoing regulatory review of the deal between Lahey Health and Beth Israel Deaconess Medical Center, which seeks to create a system in Massachusetts to rival giant Partners HealthCare.

For both deals, the involved health systems touted the potential financial benefits for patients. Lahey and Beth Israel said that having a challenger to Partners will significantly bring down prices in the greater Boston area.

But Ben Isgur, leader of PricewaterhouseCoopers’ Health Research Institute, told FierceHealthcare that while the jury is still out on whether these deals will benefit for patients in the long-term, significant cost savings haven’t appeared in the short-term.

“Especially in the short-term, there’s not a lot of data out there that shows it will reduce costs,” Isgur said. “It’s a market play.”

Other experts have expressed the same concern, and in some cases, have warned that these deals could even lead to higher prices. In addition, a study released earlier this year suggests that the rapid pace of consolidation may pose a risk to patient safety.

Isgur said, though, that immediate benefits could play out in an improved patient experience and access to more convenient sites of care, such as urgent care centers or telemedicine from home.

Consolidation can also make it easier for providers to jump into the latest technologies, he said, by enhancing their workforce and bringing in additional money, which could pay off for patients more immediately, too.


Hospital prices are about to go public

Dec 26, 2018 / By: Kaitlin Schroeder, Journal-News.com

Prices hospitals charge for their services will all go online Jan. 1 under a new federal requirement, but patient advocates say the realities of medical-industry pricing will make it difficult for consumers to get much out of the new data.

federal rule requires all hospitals to post online a master list of prices for the services they provide so consumers can review them starting Jan. 1.

The health care industry nationally has a reputation for having little price transparency, which can make it difficult for consumers to price compare. But the hospital’s master list prices, sometimes called a chargemaster, is also not a complete look, consumer advocates say.

That’s because the final bill a patient receives is almost never the same as the sticker price for the services they received. Insurance companies negotiate discounts on the sticker prices. Co-pays, co-insurance, deductibles also add other layers of complexity that bring discounts or increased costs before a final charge is determined.

“The list prices are so high that the vast majority of hospitals don’t even try to collect list prices from uninsured patients,” said Benedic Ippolito, with the American Enterprise Institute, who has researched hospital list prices.

The federal rule is being brought out as a measure to improve competition and help educate consumers.

“We are just beginning on price transparency,” Seema Verma, head of U.S. Centers for Medicare & Medicaid told the Associated Press. “We know that hospitals have this information and we’re asking them to post what they have online.”

But real transparency comes when consumers can easily see what they will pay to a provider based on their insurance benefits, said Thomas Campanella, Baldwin Wallace University health care MBA program director. He said some insurance companies are providing that information through price comparison tools.

“I almost see it being more of a political ‘look at what we did,’” Campanella said of the requirement to post list prices.

Kettering Health Network, which has eight hospitals in the Dayton, Ohio area, said the chargemaster will be posted on its patient pricing webpage after Jan. 1. Premier Health, which has three hospitals in the same region, said the information will be on its hospitals’ websites by Jan. 1. and consumers will find the list of charges where they currently find other pricing, insurance and billing information.




Photo: Nick Graham/Staff


5 Reasons the 3rd Ortho Value-Based Care Conference Will Be the Best Event You Attend in 2019

12-26-2018 / Kain, Zeev

I’m excited to announce the 3rd Interdisciplinary Conference on Orthopedic Value based Care taking place on January 18-20, 2018 in beautiful Newport Beach, California. We’ve planned this conference to be even better than last 2 years highly-rated event!

Here’s five reasons it should be on your to-do list:

  1. One Unique Team Concept

The mission of this conference is to break the silos that exist in a patient’s orthopaedic journey. This is the only conference that brings in speakers that represent players from across the episode: orthopedic surgeons, nurses, physical therapists, healthcare executives, anesthesiologists, patients, digital health experts and futurists. In the same vein, we expect surgical teams to attend and take this opportunity to learn from each other and work toward better patient outcomes together. This worked well at last year’s conference where 40% of the participants were part of a hospital team.

  1. Two Innovative Cadaveric Workshops
    On Friday there are 2 cadaveric workshops that will focus on innovative surgical orthopedic procedures and US based regional anesthesia. Plenty of opportunity to experience new devices and surgical techniques as well the most innovative regional anesthesia techniques.
  2. Three Ambulatory Boot Camps
    Orthopedic spines are heading to the outpatient area and we need to get ready. The first bootcamp will focus on the concept of fee for value in the ambulatory environment and will include practical approaches aught by all the stakeholders. The second bootcamp will focus on the nuts and bolts of building and maintaining an Orthopaedic ambulatory center and the third book camp will focus on building an enhanced recovery model for the patients who are undergoing ambulatory surgery.
  1. Four Complementary Tracks
    To be successful in the world of fee-for-value, one needs to understand all the clinical, financial and operational aspects of this new developing world. This is the ONLY conference that offer three complementary parallel tracks that the various stakeholders can attend! We choose the 4th track, ambulatory, to be held on Friday with no other programing at the same time because of the high interest in this concept.
  2. Five Times the Networking
    Each day offers four opportunities for networking, including breakfast, lunch and two breaks for exchanging best practices and comparing notes. Plus, a free meet and greet wine networking reception on Saturday night will offer a relaxed atmosphere to share insights from day one.

  3. A Six-Star Speaker Lineup
    The agenda has 38 world-class, interdisciplinary speakers. Ortho experts include speakers such as Alexander R. Vaccaro, President and Surgeon-in-Chief at Rothman Institute Orthopedics; Joseph Iannotti, Chair at Cleveland Clinic, Kevin Bozic, Chair at Dell School of Medicine and Tony Romeo from the Rothman Institute of New York. The Executive leaders include individuals such as the CMO of Humana, CMO of Optum, COO of Rothman, Vice Chancellor of UC Davis and others.

Register today!

Published Regenexx Research, Involving Stem Cells And Platelets, Shows Promise For Treating Osteoarthritis Of The Knee

BROOMFIELD, Colo., Dec, 21, 2018 /PRNewswire/ — New research from Regenexx®, which provides advanced interventional orthobiologics, shows greater potential for treating osteoarthritis of the knee with cell-based therapies. The study, published on December 13, 2018, in the Journal of Translational Medicine, was a randomized controlled trial of patients’ own bone marrow concentrate (BMC) and platelet-rich plasma products versus an exercise therapy regimen for patients with moderate knee osteoarthritis, with clinical outcomes documented over a two-year period.

The study included 48 patients, with 22 in the control group (exercise) and 26 receiving the treatment of bone marrow concentrate (which contains mesenchymal stem cells, platelets, and other cells with healing and regeneration potential) and platelet-rich plasma. All patients in the control group crossed over to the BMC treatment group at three months.

Patients who received the BMC treatment improved significantly in activity levels and stability at three months over those who followed the exercise therapy program. Over the two-year period, after receiving the BMC treatment, significant reduction in pain and increased functionality were maintained.

“To the best of our knowledge, this is the first randomized controlled trial comparing patients’ own bone marrow concentrate and therapeutic exercise for knee osteoarthritis,” said Christopher Centeno, M.D., lead researcher on the study. “While exercise therapy alleviated osteoarthritis symptoms and improved function, the specific BMC protocol, while warranting further investigation, had a greater positive impact on the patients.”

Osteoarthritis, one of the most common causes of chronic joint pain, affects more than 50 million adults in the United States. Annual costs due to medical expenses and lost wages exceed $100 billion. Current treatments include non-steroidal anti-inflammatory drugs, which are not curative and are associated with side effects; corticosteroid injections, which demonstrate only modest clinical benefits; aquatic therapies, which provide short-term benefits; and physical therapy.

While exercise or physical therapy has been shown to improve function and reduce pain, this study showed cell-based therapy to be more effective.

To review the full study and outcomes in the Journal of Translational Medicine, click here.

About Regenexx

Regenexx provides advanced interventional orthobiologics (non-surgical stem cell and blood platelet treatments) for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone. The company also provides programs for self-funded employers, enabling them to offer their employees an additional choice in care for orthopedic issues. For more information, visit www.regenexx.com or www.regenexxcorporate.com.


Amanda Roston



SOURCE Regenexx

Related Links


Early Reviews of Zimmer Biomet/Apple’s Mymobility App


December 20, 2018 / Elizabeth Hofheinz, M.P.H., M.Ed.

Approximately two months ago, Zimmer Biomet announced the mymobility app which is meant to walk patients through pre- and post-op large joint arthroplasty care.

Joshua Carothers, M.D., an orthopedic surgeon at New Mexico Orthopaedics in Albuquerque, is one of the first users of this Zimmer Biomet/Apple product. He shared his early experiences with OTW. “While our experience in the study has been limited, with just a few patients enrolled so far, people are definitely excited.”

“mymobility feels cutting-edge. Patients like using the wearable technology to guide their activity pre- and post-surgery. The basic concept of using technology to make the experience better is resonating with patients and I’m excited about using mymobility to improve care for patients with insights on things like patient complications and re-admissions, to name a couple.”

This project is of particular importance to Zimmer Biomet’s CEO Bryan Hanson. “We are incredibly excited to work with Apple to transform the knee and hip replacement experience for patients and surgeons.”

The mymobility app captures data from knee and hip replacement patients and shares it seamlessly with their doctors so that, as Jeff Williams, chief operating officer at Apple explained “They can participate in their care and recovery in a way not previously possible through traditional in-person visits. This solution will connect consumers with their doctors continuously, before and after surgery.”




Conformis readies $21m private placement


ConforMIS (NSDQ:CFMS) said this week that it inked a deal with Lincoln Park Capital Fund to sell $21 million of shares of the company’s common stock over the course of a 36-month term.

According to the terms of the deal, ConforMIS also plans to issue an additional 354,430 shares of common stock to Lincoln Park as commitment shares.

In total, the company said it will sell no more than 12,651,640 shares of common stock to Lincoln Park unless it obtains stockholder approval to issue more.

Also this month, ConforMIS announced that it would lay off roughly 10% of its workforce.